Mattias Törnerud, Capio St Görans sjukhus AB, Stockholm. Invasiv tryckmätning FFR
|
|
|
- Clementine Newton
- 10 years ago
- Views:
Transcription
1 Namn: Titel: Mattias Törnerud, Capio St Görans sjukhus AB, Stockholm Invasiv tryckmätning FFR Har mo/agit förläsararvoden från St Jude Medical.
2 Intrakoronar tryckmätning, FFR i daglig praxis 1000 angio 450 PCI 100 FFR Mattias Törnerud, Medicinkliniken Capio St Görans sjukhus
3
4
5 Visual Interpretation of Moderate Lesions: Relation to FFR Significant Not Significant FFR > 0.75 A 53% 47% correct B 49% 51% C 56% 44% FFR < 0.75 correct A 80% 20% B 67% 33% C 87% 13% Diagnostic accuracy of visual assessment is 60% Fischer AJC; 2002;90:
6 QCA vs FFR FFR Diameter stenosis%
7 What to do with intermediate lesions 40-80% Treat all of them Treat none of them Treat some of them Or throw the dize
8 65% 25%
9 FFR-interpretation non-signif. stenosis significant Specificity : ~ 100% Sensitivity : ~ 90 % (NEJM 1996; 334: )
10 IMPORTANCE OF PERFUSION TERRITORY: Large perfusion area (myocardium) MLD, cross-sectional area and stenosis resistance are identical. MLD = 1.9 mm CSA = 4.5 mm 2 Small perfusion area (myocardium)
11 IDENTICAL % STENOSIS BUT DIFFERENT PHYSIOLOGIC SIGNIFICANCE. 100 FFR = Large perfusion area (myocardium) 100 FFR = Small perfusion area (myocardium)
12 PREVIOUS MYOCARDIAL INFARCTION (DECREASED PERFUSION TERRITORY): FFR = 0.60 FFR = Normal Myocardium SCAR Normal Myocardium Anatomic stenosis severity remins unchanged but physiologic severity has decreased. FFR accounts for those changes and always gives the right result!
13 Man född -54. Lindrig walk through AP Stresseko (220 W) med ischemi i septum Man född -49. AP vid löpning. Patologiskt a-prov till 240W
14 LAD: 0,82 LCX: 0,96 LAD: 0,88 D1: 0,92
15 Man född -55. AP vid rask promenad eller Uppförsbackar. Patologiskt a-prov till 200 W LAD: 0,68 Slutresultat efter stent
16 Man född -47. BMS (3,75 x 18) i LAD dec-09 I samband med IAP. Nu anginarecidiv vid rask promenad LAD: 0,79 Slutresultat efter DEB 3,5 x 26
17 Sensitivity? Specificity?
18
19
20 Prognostic significance of reversible ischemia at MIBI-Spect Average Annual Hard Events Iskander S, Iskandrian A E JACC 1998
21
22
23
24
25 Accuracy of MIBI-SPECT Male, 69-year-old, typical angina CCS 3, positive Mibi-Spect inferior wall, Referred for intervention of severe RCA stenosis
26 MIBI-SPECT Stress Rest Male, 69-year-old, typical angina CCS 3, positive Mibi-Spect inferior wall,
27 Accuracy of MIBI-SPECT
28 Limitations of Noninvasive Imaging: 143 Patients with angiographically significant 3 vessel disease (> 70% diameter stenosis) Thallium Scan Finding % Patients No Defect 18% Single Vessel Pattern 36% Two Vessel Pattern 36% Three Vessel Pattern 10% Lima et al. J Am Coll Cardiol 2003;42:63-70
29 Accuracy of MIBI-SPECT LAD: 0,65 RCA: 0,62 LCX: 0,68 Male, 53-year-old, typical angina at exercise, CCS 3 Persantin-MIBI spect negative re-assured several times. After repeated visits at outpatient clinic: referred for angio
30 Non-ischemic lesions do not need to be treated! The DEFER Study: 5-year Event-free Survival FFR > 0.75 FFR > 0.75 Mortality / AMI per year for non-sign lesion: < 1 % PCI rate per year for non-significant lesion : 4 % Circulation 2001; 103: )
31 20 % P=0.20 P< P< DEFER PERFORM REFERENCE FFR > 0.75 FFR < 0.75
32
33
34 FLOW CHART Patient with stenoses 50% in at least 2 of the 3 major epicardial vessels Indicate all stenoses 50% considered for stenting Randomization Angiography-guided PCI FFR-guided PCI Measure FFR in all indicated stenoses Stent all indicated stenoses Stent only those stenoses with FFR year follow-up
35 ANGIO-group N=496 FFR-group N= ± ± (98%) (63%) (37%) 2.7 ± ± % 94%
36 ANGIO-group N=496 FFR-group N= (18.4) 67 (13.2)
37 ANGIO-group N=496 FFR-group N= (18.4) 67 (13.2) 15 (3.0) 9 (1.8) 55 (11.1) 37 (7.3) 47 (9.5) 33 (6.5) (8.7) 29 (5.7)
38 absolute difference in MACE-free survival FFR-guided Angio-guided 30 days 2.9% 90 days 3.8% 180 days 4.9% 360 days 5.3%
39
40
41
42 1 Year Economic Evaluation Angio Less Costly Angio Better FFR Less Costly FFR Better QALY USD
43 MACCE in SYNTAX 3VD and FAME similar definition of MACCE, including CVA and excluding CKMB 3-5 x N % SYNTAX UPPER MIDDLE LOWER FAME ALL TERCILE TERCILE TERCILE
44
45
46 Why is the results so good in the FFR group of the FAME study?
47 Intrinsic risk of death and myocardial infarction?
48 Intrinsic risk of death and myocardial infarction? chance to die or have AMI from non-ischemic lesion < 1% / year chance to die or have AMI from ischemic lesion ~ 5 % / year chance to die or have AMI from unnecessary stent ~ 3 % / year
49 stent them all : intrinsic risk 12% 12% stent the ischemic ones : intrinsic risk 12% 8%
50 Outcome of Deferred Lesions
51 Outcome of Deferred Lesions
Non-invasive FFR Using Coronary CT Angiography and Computational Fluid Dynamics Predicts the Hemodynamic Significance of Coronary Lesions
Non-invasive FFR Using Coronary CT Angiography and Computational Fluid Dynamics Predicts the Hemodynamic Significance of Coronary Lesions Andrejs Erglis, Sanda Jegere, Zanda Runkule, Ligita Zvaigzne, Dace
Cilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
FFR CT : Clinical studies
FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity
PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
Non-invasive functional testing in 2014
Non-invasive functional testing in 2014 Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Disclosures: Research grants: Edwards and Siemens Non-invasive functional testing in 2014
For the NXT Investigators
Diagnostic performance of non-invasive fractional flow reserve derived from coronary CT angiography in suspected coronary artery disease: The NXT trial Bjarne L. Nørgaard, Jonathon Leipsic, Sara Gaur,
Scott Hubbell, MHSc, RRT-NPS, C-NPT, CCT Clinical Education Coordinator/Flight RRT EagleMed
Scott Hubbell, MHSc, RRT-NPS, C-NPT, CCT Clinical Education Coordinator/Flight RRT EagleMed Identify the 12-Lead Views Explain the vessels of occlusion Describe the three I s Basic Interpretation of 12-Lead
MYOCARDIAL PERFUSION COMPUTED TOMOGRAPHY PhD course in Medical Imaging. Anne Günther Department of Radiology OUS Rikshospitalet
MYOCARDIAL PERFUSION COMPUTED TOMOGRAPHY PhD course in Medical Imaging Anne Günther Department of Radiology OUS Rikshospitalet CORONARY CT ANGIOGRAPHY (CTA) Accurate method in the assessment of possible
Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?
Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital
Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,
Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI
Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos
Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
Diagnostic and Therapeutic Procedures
Diagnostic and Therapeutic Procedures Diagnostic and therapeutic cardiovascular s are central to the evaluation and management of patients with cardiovascular disease. Consistent with the other sections,
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
Main Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
PCI vs. CABG for Left Main Disease
The EXCEL Ti Trial Design, Status, t and Timelines Gregg W. Stone, MD Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation PCI vs. CABG for Left Main Disease
RIBS V. Fernando Alfonso MD, PhD, FESC Hospital Universitario La Princesa Madrid.
A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal In-Stent Restenosis: The RIBS V Clinical Trial Fernando Alfonso MD, PhD, FESC Hospital Universitario
2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.
DISCLOSURES I have no relevant financial relationships to disclose. Cardiac Evaluation of Potential Solid Organ Transplant Recipients Michele Hamilton, MD Director, Heart Failure Program Cedars Sinai Heart
CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD
CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ Charles White MD Director of Thoracic Imaging Department of Radiology University of Maryland CORONARY ARTERY BYPASS GRAFTS First performed
Efficient Evaluation of Chest Pain
Efficient Evaluation of Chest Pain Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL No Disclosures Outline Background Chest pain pathway Indications for stress test Stress test
Section 8: Clinical Exercise Testing. a maximal GXT?
Section 8: Clinical Exercise Testing Maximal GXT ACSM Guidelines: Chapter 5 ACSM Manual: Chapter 8 HPHE 4450 Dr. Cheatham Outline What is the purpose of a maximal GXT? Who should have a maximal GXT (and
4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts
Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.
Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam
Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura
Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)
Coronary Bifurcation Treatment: Update from the European Bifurcation Club Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Disclosure Statement of Financial Interest Within the past 12 months, I
OCT STEMI: OCT guidance during stent implantation
OCT STEMI: OCT guidance during stent implantation in primary PCI. A Randomized Multicenter study with 9-month optical coherence tomography follow-up Červinka P 1,2, Kala P 3, Jakl M 2,4, Kaňovský J 3,
123 Main St NY, New York 12345 ph: (202) 555 5555 fax: (202) 555 5555
Patient Name: DOE, JOHN D. Gender: M Date of Study: 4/2/2013 Date of birth: 6/28/1962 Age: 50 Medical Record #: 45869725 Ordering Physician: JANE INTERNIST, MD History: Atypical Angina, Abn ECG, High Cholesterol,
06 Validation of risk prediction model
HA Territory-wide PCI Audit 2003-06 06 Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007 Background Participants: All HA hospitals via
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
12 Lead ECGs: Ischemia, Injury & Infarction Part 2
12 Lead ECGs: Ischemia, Injury & Infarction Part 2 McHenry Western Lake County EMS Localization: Left Coronary Artery Right Coronary Artery Right Ventricle Septal Wall Anterior Descending Artery Left Main
Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine
Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics Yen Tibayan, M.D. Division of Cardiovascular Medicine Case Presentation 69 y.o. woman calls 911 with the complaint of
6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.
The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies Christoph Hehrlein, University Clinic Freiburg i.br. Germany Disclosure Statement of Financial Interest Within the past 12 months,
Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos. Eulógio E Martinez
Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos Eulógio E Martinez IVUS vs luminologia Positivo Negativo estenose TCE oclusão CD sístole
Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up
Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS
Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada
Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada April 2009 Jack V. Tu, MD PhD FRCPC CANADA RESEARCH CHAIR IN HEALTH SERVICES RESEARCH Institute
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France
Noninvasive testing can provide useful information for
CONTINUING EDUCATION Roles of Nuclear Cardiology, Cardiac Computed Tomography, and Cardiac Magnetic Resonance: Noninvasive Risk Stratification and a Conceptual Framework for the Selection of Noninvasive
ST Segment Elevation Nothing is ever as hard (or easy) as it looks
ST Segment Elevation Nothing is ever as hard (or easy) as it looks Cameron Guild, MD Division of Cardiology University of Mississippi Medical Center February 17, 2012 Objectives 1. Describe the electrical
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
J_ID: Z7V Customer A_ID: 2011_PCI_Guideline Cadmus Art: CCD23390 Date: 3-November-11 Stage: Page: 1 ID: kandasamy.d I Black Lining: [ON] I Time: 12:16 I Path: N:/3b2/CCD#/Vol00000/110478/APPFile/JW-CCD#110478
LEADERS: 5-Year Follow-up
LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS
Renovascular Hypertension
Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension
The left internal mammary artery (LIMA) is the
Case Report 925 Direct Stenting of a Transradial Left Internal Mammary Artery Graft Wei-Chin Hung, MD; Bih-Fang Guo, MD, PhD; Chiung-Jen Wu, MD; Chien-Jen Chen, MD; Chih-Yuan Fang, MD Taking the transfemoral
Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation
Original Contribution Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation Cynthia A. Yock, MS, J. Michael Isbill, MS, Spencer B. King III, MD, Mark
Majestic Trial 12 Month Results
Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.
Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting
on behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial
Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial David J. Cohen, Tara A. Lavelle, Patrick W. Serruys, Friedrich
Abstract. n engl j med 360;3 nejm.org january 15, 2009 213
The new england journal of medicine established in 1812 january 15, 2009 vol. 360 no. 3 Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention Pim A.L. Tonino, M.D.,
Early And Late Outcome For Single Versus Double Stenting For Bifurcational Coronary Artery Lesions
ORIGINAL CONTRBUTION / CLINICAL INVESTIGATION Early And Late Outcome For Single Versus Double Stenting For Bifurcational Coronary Artery Lesions Aram J. Mirza Correspondence: Dr. Aram J.Mirza Interventional
Cardiac CT Emerging Role and Current Indications
Cardiac CT Emerging Role and Current Indications Dr. Felix Keng MBBS, FRCP (Lond), FAMS, Dip CBNC, Dip CBCCT, MMed (Int Med), FAPSC Director, Nuclear Cardiology National Heart Centre, Singapore Adjunct
Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
CARDIAC RISKS OF NON CARDIAC SURGERY
CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management
How should we treat atrial fibrillation in heart failure
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città
Pre-Operative Cardiac Evaluation Kalpana Jain, MD
Pre-Operative Cardiac Evaluation Kalpana Jain, MD Cardiac evaluation is an integral part of pre-op evaluation. Perioperative cardiac events are common causes of mortality. Major cardiac complications associated
The heart walls and coronary circulation
CHAPTER 1 The heart walls and coronary circulation The heart is located in the central-left part of the thorax (lying on the diaphragm) and is oriented anteriorly, with the apex directed forward, downward,
Antonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)
CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99) March 2014 2014 MVP Health Care, Inc. CHAPTER 9 CHAPTER SPECIFIC CATEGORY CODE BLOCKS I00-I02 Acute rheumatic fever I05-I09 Chronic rheumatic heart
INTRODUCTION TO EECP THERAPY
INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and
BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY
BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY American Osteopathic Association and the American College of Osteopathic Internists Specific Requirements For Osteopathic Subspecialty Training In Cardiology
Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015
STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015 PROJECT TITLE: Analysis of ECG Exercise Stress Testing and Framingham Risk Score in Chest Pain Patients PRIMARY SUPERVISOR NAME: Dr. Edward Tan DEPARTMENT:
Imaging of Thoracic Endovascular Stent-Grafts
Imaging of Thoracic Endovascular Stent-Grafts Tariq Hameed, M.D. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana Disclosures: No relevant financial
Specific Basic Standards for Osteopathic Fellowship Training in Cardiology
Specific Basic Standards for Osteopathic Fellowship Training in Cardiology American Osteopathic Association and American College of Osteopathic Internists BOT 07/2006 Rev. BOT 03/2009 Rev. BOT 07/2011
Māori Pathways to and Through Health Care for STEMIs in New Zealand. Summer Studentship Research by Ellie Tuzzolino- Smith
Māori Pathways to and Through Health Care for STEMIs in New Zealand Summer Studentship Research by Ellie Tuzzolino- Smith Terminology & Current Practice STEMI: S-T elevation Myocardial Infarction. Determined
RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department
RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital
Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity
Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea
Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases
Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases T. Masood,T. Sagheer,D. Jan,N. Qamar,A.M.A. Faruqui ( National Institute of Cardiovascular Diseases (NICVD), Karachi.
INSTEAD at 5-year follow-up shifts the expectations for endovascular treatment
INSTEAD at 5-year follow-up shifts the expectations for endovascular treatment Christoph A. Nienaber, MD, FACC University Heart Center Rostock Department of Medicine I - Cardiology [email protected]
Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better
Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Marian Taylor, M.D. Medical University of South Carolina Director, Cardiac Rehabilitation I have no disclosures.
The Bioresorbable Vascular Stent Dr Albert Ko
The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of
The Cardiac Society of Australia and New Zealand
The Cardiac Society of Australia and New Zealand Guidelines on Support Facilities for Coronary Angiography and Percutaneous Coronary Intervention (PCI) including Guidelines on the Performance of Procedures
Ischemia and Infarction
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Ischemia and Infarction HST.035 Spring 2003 In the US: ~50% of deaths are due to
Drug-Eluting Coronary Stents. Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate
Drug-Eluting Coronary Stents Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate Outline Coronary Artery Disease Evolution of Percutaneous Coronary Intervention
The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program
The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program Jean Fajadet, MD, FESC Clinique Pasteur - Toulouse - France Disclosure statement Nothing to disclose Dedicated Delivery
Vascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial
Vascular Quality Initiative - Carotid Artery Stent Last Name First Name Middle Initial Date of Birth Medical Record Social Security General Information Patient Data Zip/Postal Code Gender Male Female Ethnicity
California Health and Safety Code, Section 1256.01
California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program
Computed Tomography, Head Or Brain; Without Contrast Material, Followed By Contrast Material(S) And Further Sections
1199SEIU BENEFIT AND PENSION FUNDS High Tech Diagnostic Radiology and s # 1 70336 Magnetic Resonance (Eg, Proton) Imaging, Temporomandibular Joint(S) 2 70450 Computed Tomography, Head Or Brain; Without
12-Lead EKG Interpretation. Judith M. Haluka BS, RCIS, EMT-P
12-Lead EKG Interpretation Judith M. Haluka BS, RCIS, EMT-P ECG Grid Left to Right = Time/duration Vertical measure of voltage (amplitude) Expressed in mm P-Wave Depolarization of atrial muscle Low voltage
Journal of the American College of Cardiology Vol. 38, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.
Journal of the American College of Cardiology Vol. 38, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01408-5 Prognostic
